This content is promotional.
The mAbXmise quantification kits are intended to monitor the concentration of therapeutic monoclonal antibodies (mAbs) in samples from patients treated with these mAbs. The kit is a quantitative assay. The test can be performed on plasma (EDTA, heparin or citrate collection tubes) and serum. Assay results are intended to be used by healthcare professionals. Before use, it is important to carefully read the instructions provided with the product.
This space contains information on medical devices, the use of which is reserved for healthcare professionals. In application of the law of December 29, 2011 relating to the strengthening of health security, I certify that I am a health professional and therefore be authorized to access this information.
mAbXmise monoclonal antibodies quantification kits are In Vitro Diagnostic Medical Devices for laboratory professional use and CE-IVD labeled for Europe by BSI. Assay results are intended to be used by healthcare professionals. The kits are designed to perform absolute quantification by LC-MS (Liquid Chromatography – Mass spectrometry) of specific therapeutic monoclonal antibodies (mAbs) in a patient sample. Assay results are intended to be used by healthcare professionals. Before use, it is important to carefully read the instructions provided with the product. The products are non-refundable. The mAbXmise Kit described has not been cleared by any regulatory entity for diagnostic purposes outside of Europe. Proteomics mAbXmise Kits are not available for sale in all countries.
I am a healthcare professional
Close window if you are not a healthcare professional
Application
Quantification of procalcitonin in
clinical or preclinical samples.
Specific labelling
Uniform-15N >99%
Description
Procalcitonin (PCT) is a biomarker that reacts with high sensitivity and specificity to generalized infection and sepsis. It correlates better than all other existing parameters to the inflammatory activity of the immune system and can be used to diagnose and to monitor severe bacterial infections and sepsis.
Recently, strong evidence supports the reduction of antibiotics using PCT-guided antibiotic stewardship protocols. PCT guidance could help reduce the initial antibiotic prescription rates and also the antibiotic treatment duration.
This product is for research use only and is not intended for diagnostic or therapeutic use.
10 µg
For any other quantities, please contact us
Custom clearance and freight insurance costs to be borne by the customer.
Legal:
This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.
